Eidos Therapeutics, Inc. Insider Trading for June 2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Eidos Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Eidos Therapeutics, Inc. for June 2018.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26 2018 | EIDX | Eidos Therapeutics ... | BridgeBio Pharma LLC | 10% Owner | Option Exercise | C | 0.00 | 12,832,123 | 0 | 0 | |
| Jun 26 2018 | EIDX | Eidos Therapeutics ... | BridgeBio Pharma LLC | 10% Owner | Option Exercise | C | 0.00 | 2,909,029 | 0 | 0 | |
| Jun 26 2018 | EIDX | Eidos Therapeutics ... | BridgeBio Pharma LLC | 10% Owner | Option Exercise | X | 0.00 | 332,262 | 0 | 2,909,029 | |
| Jun 26 2018 | EIDX | Eidos Therapeutics ... | BridgeBio Pharma LLC | 10% Owner | Option Exercise | X | 10.83 | 332,262 | 3,599,992 | 0 | |
| Jun 26 2018 | EIDX | Eidos Therapeutics ... | BridgeBio Pharma LLC | 10% Owner | Buy | P | 17.00 | 1,000,000 | 17,000,000 | 19,614,655 | 18.6 M to 19.6 M (+5.37 %) |
| Jun 26 2018 | EIDX | Eidos Therapeutics ... | BridgeBio Pharma LLC | 10% Owner | Payment of Exercise | F | 17.00 | 211,762 | 3,599,954 | 18,614,655 | 18.8 M to 18.6 M (-1.12 %) |
| Jun 26 2018 | EIDX | Eidos Therapeutics ... | BridgeBio Pharma LLC | 10% Owner | Buy | C | 0.00 | 18,826,417 | 0 | 18,826,417 | 0 to 18.8 M |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Shah Rajeev M. | Director | Option Exercise | C | 0.00 | 922,950 | 0 | 0 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Shah Rajeev M. | Director | Buy | P | 17.00 | 1,058,824 | 18,000,008 | 2,162,671 | 1.1 M to 2.2 M (+95.92 %) |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Shah Rajeev M. | Director | Buy | C | 0.00 | 1,103,847 | 0 | 1,103,847 | 0 to 1.1 M |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Option Exercise | C | 0.00 | 12,832,123 | 0 | 0 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Option Exercise | C | 0.00 | 2,909,029 | 0 | 0 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Option Exercise | X | 0.00 | 332,262 | 0 | 2,909,029 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Option Exercise | X | 10.83 | 332,262 | 3,599,992 | 0 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Buy | P | 17.00 | 1,000,000 | 17,000,000 | 19,614,655 | 18.6 M to 19.6 M (+5.37 %) |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Payment of Exercise | F | 17.00 | 211,762 | 3,599,954 | 18,614,655 | 18.8 M to 18.6 M (-1.12 %) |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Buy | C | 0.00 | 18,826,417 | 0 | 18,826,417 | 0 to 18.8 M |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | C | 0.00 | 12,832,123 | 0 | 0 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | C | 0.00 | 2,909,029 | 0 | 0 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | X | 0.00 | 332,262 | 0 | 2,909,029 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | X | 10.83 | 332,262 | 3,599,992 | 0 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Buy | P | 17.00 | 1,000,000 | 17,000,000 | 19,614,655 | 18.6 M to 19.6 M (+5.37 %) |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Payment of Exercise | F | 17.00 | 211,762 | 3,599,954 | 18,614,655 | 18.8 M to 18.6 M (-1.12 %) |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Buy | C | 0.00 | 18,826,417 | 0 | 18,826,417 | 0 to 18.8 M |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | Huh Hoyoung | Director | Option Exercise | A | 17.00 | 83,720 | 1,423,240 | 83,750 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 922,950 | 0 | 0 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 17.00 | 1,058,824 | 18,000,008 | 2,162,671 | 1.1 M to 2.2 M (+95.92 %) |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | C | 0.00 | 1,103,847 | 0 | 1,103,847 | 0 to 1.1 M |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 922,950 | 0 | 0 | |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 17.00 | 1,058,824 | 18,000,008 | 2,162,671 | 1.1 M to 2.2 M (+95.92 %) |
| Jun 22 2018 | EIDX | Eidos Therapeutics ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | C | 0.00 | 1,103,847 | 0 | 1,103,847 | 0 to 1.1 M |